XASX
CMP
Market cap30mUSD
Jul 10, Last price
0.23AUD
1D
4.55%
1Q
-17.86%
Jan 2017
-73.56%
IPO
-74.16%
Name
Compumedics Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Compumedics Limited is a global medical technology enterprise engaged in the full lifecycle of designing, producing, marketing, and distributing advanced diagnostic medical devices. Its market reach extends across Australia, the Asia Pacific region, the Americas, Europe, and the Middle East. The company's product portfolio is primarily focused on solutions for sleep and neurological disorders. For sleep diagnostics, offerings include sophisticated PSG:EEG amplification systems like the Grael 4K, portable recording units such as the Somté PSG and Siesta 802, wearable monitoring devices like Somfit/Somfit Pro, and transcutaneous monitors (e.g., TCM5 FLEX). In the field of neurology, Compumedics supplies devices like the ONsight A.V.S. for home ambulatory studies, a variety of EEG amplifiers (e.g., Grael 4K-EEG, Grael LT EEG), comprehensive long-term EEG monitoring systems (Neuvo 64-512 Channel LTM), and specialized EMG/EP systems (including Xegis Forte and Xegis G:NEO). Complementing its hardware, the company develops an extensive range of software, featuring the Profusion Sleep and EEG platforms, Profusion neXus 360 (a web-based system for patient data and lab management), a Multi-Modal Neuroimaging Suite, and workflow optimization tools like Profusion neXus Laboratory Management and Scheduler. Other software offerings include HD Digital Video integration and various specialized applications. Furthermore, Compumedics provides magnetoencephalography systems, cutting-edge brain research technologies, services for pharmaceutical clinical trials and research, as well as a diverse array of accessories and consumables crucial for diagnostic and research endeavors. Established in 1987, Compumedics Limited is based in Abbotsford, Australia, and functions as a subsidiary of D & DJ Burton Holdings Pty Ltd.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||